Fannie Mae, Freddie Mac shares tumble after conservatorship comments
SAN FRANCISCO—Kira Wampler, a director at Doximity , Inc. (NYSE:DOCS), executed a sale of 2,000 shares of the company’s Class A common stock on March 3, 2025. The shares were sold at a price of $70.89 each, resulting in a total transaction value of $141,780. The transaction comes as Doximity, currently valued at $13 billion, trades near its 52-week high after delivering a remarkable 144% return over the past year.
The sale was conducted under a Rule 10b5-1 trading plan, which Wampler adopted on November 12, 2024. Following this transaction, Wampler’s direct ownership in Doximity stands at 16,618 shares. For comprehensive insider trading analysis and 16 additional key insights about Doximity, investors can access detailed reports on InvestingPro.
In addition to the sale, Wampler also exercised stock options to acquire 2,000 shares of Class B common stock, which were converted into Class A shares. The exercise price was set at $1.54 per share. This transaction was part of a stock option plan that vested in monthly installments starting from March 27, 2020.
Doximity, Inc., a digital platform for medical professionals, is headquartered in San Francisco, California.
In other recent news, Doximity Inc. reported impressive financial results for its third fiscal quarter, with a notable 25% year-over-year revenue increase, reaching $168 million. This figure surpassed both the company’s guidance and analysts’ expectations, as highlighted by Mizuho (NYSE:MFG) Securities. The company’s EBITDA also saw a significant 39% year-over-year growth, outperforming previous estimates. Following these results, several analysts have adjusted their outlooks on Doximity. Jefferies raised its price target to $88, maintaining a Buy rating, while Piper Sandler upgraded the stock to Overweight and increased its target to $78. Needham also raised its price target to $82, maintaining a Buy rating, citing Doximity’s strong upselling and new product offerings. KeyBanc reiterated its Overweight rating and a $65 price target, noting the company’s accelerating top- and bottom-line momentum. These developments reflect a broad consensus among analysts regarding Doximity’s strong market position and growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.